About Us

PharmNovo AB is a Swedish clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company has developed a novel compound portfolio based on a new type of selective delta opioid receptor agonists (DORAs), intended to provide effective neuropathic pain relief without the adverse side effects of conventional opioids. The company’s lead candidate, PN6047, is currently in the final stages of phase I studies and is shown to effectively reduce neuropathic pain in preclinical studies. PharmNovo is preparing for phase II studies with the lead candidate in chronic neuropathic pain and potentially in other areas, for example chronic cough and opioid withdrawal syndrome (OWS). To learn more, visit pharmnovo.com and follow PharmNovo on LinkedIn.